Department of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius v. 16, SE-106 91 Stockholm, Sweden.
Biochemistry. 2012 Jan 10;51(1):126-37. doi: 10.1021/bi201745g. Epub 2011 Dec 14.
The link between many neurodegenerative disorders, including Alzheimer's and Parkinson's diseases, and the aberrant folding and aggregation of proteins has prompted a comprehensive search for small organic molecules that have the potential to inhibit such processes. Although many compounds have been reported to affect the formation of amyloid fibrils and/or other types of protein aggregates, the mechanisms by which they act are not well understood. A large number of compounds appear to act in a nonspecific way affecting several different amyloidogenic proteins. We describe here a detailed study of the mechanism of action of one representative compound, lacmoid, in the context of the inhibition of the aggregation of the amyloid β-peptide (Aβ) associated with Alzheimer's disease. We show that lacmoid binds Aβ(1-40) in a surfactant-like manner and counteracts the formation of all types of Aβ(1-40) and Aβ(1-42) aggregates. On the basis of these and previous findings, we are able to rationalize the molecular mechanisms of action of nonspecific modulators of protein self-assembly in terms of hydrophobic attraction and the conformational preferences of the polypeptide.
许多神经退行性疾病(包括阿尔茨海默病和帕金森病)与蛋白质的异常折叠和聚集之间存在关联,这促使人们全面寻找具有抑制这些过程潜力的小分子有机化合物。尽管已经报道了许多化合物可以影响淀粉样纤维和/或其他类型的蛋白质聚集体的形成,但它们的作用机制尚不清楚。大量化合物似乎以非特异性方式作用,影响几种不同的淀粉样蛋白原性蛋白质。我们在这里详细研究了一种代表性化合物拉库米德(lacamoid)在抑制与阿尔茨海默病相关的淀粉样β肽(Aβ)聚集的作用机制。我们表明,拉库米德以表面活性剂样的方式与 Aβ(1-40)结合,并阻止所有类型的 Aβ(1-40)和 Aβ(1-42)聚集体的形成。基于这些和以前的发现,我们能够根据疏水性吸引力和多肽的构象偏好,合理推断蛋白质自组装的非特异性调节剂的作用分子机制。